← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Green Jeremy
10% Owner | Director
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001650527
Purchase history
- Companies traded
- 4
- Purchases · 12M
- 1
- Purchases · 24M
- 4
- Average purchase
- $2.8M
- Median purchase
- $486.5K
- Gross purchase value
- $11.3M
Companies: ADC Therapeutics SA | Attovia Therapeutics, Inc. | FATE THERAPEUTICS INC | Shattuck Labs, Inc.
4 SEC accession(s) · 4 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-08-07 | Attovia Therapeutics, Inc. | ATTO | 10% Owner | $10.2M | Open filing |
| 2024-12-26 | FATE THERAPEUTICS INC | FATE | Director | 10% Owner | $668.6K | Open filing |
| 2024-12-13 | ADC Therapeutics SA | ADCT | 10% Owner | $304.5K | Open filing |
| 2024-12-06 | Shattuck Labs, Inc. | STTK | Director | 10% Owner | $166.7K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 2Small Sample | 50.0% (2/4) | 50.0% (1/2) | +1.8% | +1.8% | -1.9% |
| 20D | 2Small Sample | 50.0% (2/4) | 50.0% (1/2) | +11.4% | +11.4% | -4.3% |
| 60D | 1Small Sample | 33.3% (1/3) | 100.0% (1/1) | +4.4% | +4.4% | +4.4% |
| 120D | 1Small Sample | 33.3% (1/3) | 100.0% (1/1) | +93.7% | +93.7% | +93.7% |
Research patterns
- First purchase in 12M
- 1/1
- Large purchase ≥ $100k
- 4/4
- Cluster buying · 15D
- 4/4
- Buying the dip
- 1/1
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.